Report overview
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000.
This report aims to provide a comprehensive presentation of the global market for G-CSF Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding G-CSF Biosimilars. This report contains market size and forecasts of G-CSF Biosimilars in global, including the following market information:
Global G-CSF Biosimilars Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global G-CSF Biosimilars Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five G-CSF Biosimilars companies in 2022 (%)
The global G-CSF Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for G-CSF Biosimilars in US$ by the following Product Segments: Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor
Company profiles are primarily based on public domain information including company
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Pfizer
Novartis
Roche
We surveyed the G-CSF Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global G-CSF Biosimilars Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global G-CSF Biosimilars Market Segment Percentages, by Type, 2022 (%)
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Global G-CSF Biosimilars Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global G-CSF Biosimilars Market Segment Percentages, by Application, 2022 (%)
Blood Disorders
Oncology Diseases
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
Global G-CSF Biosimilars Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global G-CSF Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies G-CSF Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies G-CSF Biosimilars revenues share in global market, 2022 (%)
Key companies G-CSF Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
Key companies G-CSF Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Outline of Major Chapters:
Chapter 1: Introduces the definition of G-CSF Biosimilars, market overview.
Chapter 2: Global G-CSF Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of G-CSF Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of G-CSF Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global G-CSF Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
